An adenosine A2A receptor antagonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

ST1535

Item No. 10611

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-amine
CAS Number
496955-42-1
Molecular Formula
C12H16N8
Formula Weight
272.3
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMF: 5mg/mLDMSO: 5mg/mLDMSO:PBS (pH 7.2) (1:9): 0.1mg/mL
λmax
233, 290 nm
SMILES
CCCCC1=NC(N)=C2C(N(C)C(N3N=CC=N3)=N2)=N1
InChi Code
InChI=1S/C12H16N8/c1-3-4-5-8-16-10(13)9-11(17-8)19(2)12(18-9)20-14-6-7-15-20/h6-7H,3-5H2,1-2H3,(H2,13,16,17)
InChi Key
CYYQMAWUIRPCNW-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $134

    Add

    10 mg

    $228

    Add

    25 mg

    $530

    Add

    50 mg

    $795

    Add
    Product Description

    ST1535 is an adenosine A2A receptor antagonist.1 It is selective for adenosine A2A over A1 receptors (Kis = 2.3 and 107 nM, respectively, in radioligand binding assays). ST1535 inhibits agonist-induced production of cAMP in CHO cells expressing adenosine A2A receptors (IC50 = 353 nM). In vivo, ST1535 (10 and 20 mg/kg) reduces haloperidol-induced catalepsy in mice. It reduces the number of jaw tremors in a rat model of Parkinsonian jaw tremors induced by tacrine (Item No. 70240).2 ST1535 (20 and 40 mg/kg) increases locomotor activity and reverses motor disabilities in a marmoset model of MPTP-induced Parkinson’s disease.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Stasi, M.A., Borsini, F., Varani, K., et al. ST 1535: a preferential A2A adenosine receptor antagonist. Int. J. Neuropsychopharmacol. 9(5), 575-584 (2006).

    2. Tronci, E., Simola, N., Borsini, F., et al. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur. J. Pharmacol. 566(1-3), 94-102 (2007).

    3. Rose, S., Jackson, M.J., Smith, L.A., et al. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. Eur. J. Pharmacol. 546(1-3), 82-87 (2006).